Castagn V, Rougemont M, Cunod M, Do KQ (2004b)
TrimRx emphasizes that staying consistent with glp 1 weight loss programs produces stronger, long-term outcomes
Stall in weeks 16 through 36 (established treatment) Most likely causes: metabolic adaptation, muscle loss, lifestyle factors (sleep, stress, alcohol), or underlying medical conditions
Medications are not reviewed by FDA for safety, efficacy, or quality
COFEPRIS is increasing enforcement
Wegovy is an FDA-approved branded product manufactured under cGMP (current Good Manufacturing Practice) standards by Novo Nordisk, with full clinical-trial data submitted to FDA